Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “BRAF Gene Mutation”

225 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 225 results

Early research (Phase 1)Looking for participantsNCT06902376
What this trial is testing

XL092 and Cemiplimab in BRAF WT Thyroid Cancer

Who this might be right for
Anaplastic Thyroid CancerThyroid CancerBRAF Mutation-Related Tumors
UNC Lineberger Comprehensive Cancer Center 12
Testing effectiveness (Phase 2)WithdrawnNCT02115035
What this trial is testing

A Single Agent Study to Evaluate the Overall Response Rate, Safety and Tolerability of Orally Administered Vemurafenib

Who this might be right for
Multiple Myeloma
University of Arkansas
Early research (Phase 1)Ended earlyNCT01611675
What this trial is testing

Leflunomide+Vemurafenib in V600 Mutant Met. Melanoma

Who this might be right for
Melanoma
Massachusetts General Hospital 3
Testing effectiveness (Phase 2)Ended earlyNCT04390243
What this trial is testing

Binimetinib and Encorafenib for the Treatment of Pancreatic Cancer in Patients With a Somatic BRAF V600E Mutation

Who this might be right for
Locally Advanced Pancreatic CarcinomaMetastatic Pancreatic CarcinomaRecurrent Pancreatic Carcinoma+2 more
Academic and Community Cancer Research United 6
Not applicableStudy completedNCT03139513
What this trial is testing

Adult Participants With BRAF V600 Mutation-Positive Advanced Melanoma Treated With Cobimetinib (Cotellic®) During the French Early Access Program (Temporary Authorization for Use [TAU])

Who this might be right for
Melanoma
Hoffmann-La Roche 200
Testing effectiveness (Phase 2)UnknownNCT05102292
What this trial is testing

The Efficacy and Safety of HLX208 in Advanced Anaplastic Thyroid Cancer (ATC) With BRAF V600 Mutation

Who this might be right for
Anaplastic Thyroid CancerATC
Shanghai Henlius Biotech 25
Early research (Phase 1)Study completedNCT01351103
What this trial is testing

LGK974 in Patients With Malignancies Dependent on Wnt Ligands

Who this might be right for
Pancreatic CancerBRAF Mutant Colorectal CancerMelanoma+5 more
Novartis Pharmaceuticals 185
Not applicableStudy completedNCT04911998
What this trial is testing

A Prospective Observational Study on Targeted Therapy for Unresectable or Metastatic BRAFV600E Mutant Melanoma Patients

Who this might be right for
Melanoma (Skin)Metastatic MelanomaBRAF V600 Mutation
Pierre Fabre Medicament 400
Testing effectiveness (Phase 2)Study completedNCT02039947
What this trial is testing

Study to Evaluate Treatment of Dabrafenib Plus Trametinib in Subjects With BRAF Mutation-Positive Melanoma That Has Metastasized to the Brain

Who this might be right for
Melanoma and Brain Metastases
Novartis Pharmaceuticals 127
Not applicableNo Longer AvailableNCT04507919
What this trial is testing

Managed Access Program Cohort Treatment Plan CTMT212X2002I to Provide Access to Trametinib and Dabrafenib Combination Therapy for Patients With BRAF V600 Mutation-positive Advanced Non-Small Cell Lung Cancer

Who this might be right for
Small Cell Lung Carcinoma
Novartis Pharmaceuticals
Not applicableLooking for participantsNCT07022457
What this trial is testing

UK ENcorafenib and BInimetinib Real-world Study in Melanoma

Who this might be right for
Metastatic Melanoma, BRAF V600 Mutation Positive
Pierre Fabre Ltd 50
Early research (Phase 1)Study completedNCT01449058
What this trial is testing

A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors

Who this might be right for
Advanced and Selected Solid TumorsAMLHigh Risk and Very High Risk MDS
Array BioPharma 139
Not applicableStudy completedNCT02450149
What this trial is testing

Single-arm Study to Evaluate the Safety and Efficacy of Sorafenib, in Subjects With BRAF Mutation Refractory Solid Tumors

Who this might be right for
Refractory Solid Tumors
Samsung Medical Center 1
Early research (Phase 1)Study completedNCT02608034
What this trial is testing

Investigate the Effect of Itraconazole and Rifampin on Pharmacokinetics (PK) of Vemurafenib at Steady State

Who this might be right for
Metastatic Melanoma, BRAF V600 Mutation Positive
Genentech, Inc. 32
Not applicableStudy completedNCT02663232
What this trial is testing

Study to Analyze Mutations in V600 BRAF Oncogen in Participants With Metastatic Melanoma

Who this might be right for
Metastatic Cancers
Hoffmann-La Roche 264
Testing effectiveness (Phase 2)Active Not RecruitingNCT04074096
What this trial is testing

Binimetinib Encorafenib Pembrolizumab +/- Stereotactic Radiosurgery in BRAFV600 Melanoma With Brain Metastasis

Who this might be right for
Malignant MelanomaBRAF V600 MutationBrain Metastases
UNICANCER 10
Testing effectiveness (Phase 2)Not Yet RecruitingNCT05275374
What this trial is testing

XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation

Who this might be right for
CancerBRAF V600 MutationMelanoma+3 more
Xynomic Pharmaceuticals, Inc. 221
Large-scale testing (Phase 3)Study completedNCT01227889
What this trial is testing

A Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma

Who this might be right for
Cancer
GlaxoSmithKline 251
Not applicableActive Not RecruitingNCT05370469
What this trial is testing

Real-Time Monitoring of Symptoms in Lung Cancer Patients Receiving Oral Targeted Therapies

Who this might be right for
Lung CancerEGFR Gene MutationEGFR+6 more
University of Virginia 30
Testing effectiveness (Phase 2)UnknownNCT05900219
What this trial is testing

Efficacy and Safety of HL-085 Combined With Vemurafenib in BRAF V600E Patients With Non-small Cell Lung Cancer: a Phase II Clinical Study

Who this might be right for
Non-small-cell Lung Cancer
Shanghai Kechow Pharma, Inc. 75
Load More Results